Approximately 10% of Ashkenazi Jewish (AJ) women with breast cancer (BC) carry a founder mutation in BRCA1 or BRCA2. The...
...BRCA2 gene patents, in the eligibility of all human and presumably other gene patents. This article argues that while pa...
...BRCA2, and TP53 genes. Two cases harbored previously unreported mutations in CHEK2, the c.507delT and c.38A>G, leading t...
Germline mutations in the BRCA2 cancer susceptibility gene are associated with an increased risk of pancreatic cancer (P...
Carriers of a germline mutation in the BRCA genes, in particular BRCA2, have an increased risk of developing pancreatic ...
...BRCA2 mutations were 3.9% (16/409) and 6.6% (27/409), respectively; the mutation rate of BRCA2 was 1.7-fold higher than ...
...BRCA2. These cases raise the question of whether or not Single Site BRACAnalysis for a known familial BRCA mutation is a...
...BRCA2) completed study instruments at T1 and T2, and 48 at T3. Eighteen women (32%) were recalled for additional imaging...
...BRCA2 cases. Additional research on the molecular mechanisms involved in the loss of PR in this population is warranted ...
...BRCA2). This decision can affect patent eligibility for inventions related to biomarkers, particularly genetic biomarker...
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
